GALT: Other NASH play BLRX @ .90s. BioLineRX did a $25M secondary today that sent the stock to .90s. The great move in GALT is a set-up for BLRX now that the secondary is out of the way and BLRX is flush. Novartis is the BLRX partner on the NASH liver drug. Link: http://www.fiercebiotech.com/biotech/novartis-partner-biolinerx-licenses-nash-drug-after-joint-evaluation